Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Combo therapy reduces risk of progression, death
10-11-2017
SHARING OPTIONS:

COPENHAGEN, Denmark—Top-line results were released in late August for the Genmab A/S Phase 3 ALCYONE study in patients newly diagnosed with multiple myeloma who are not candidates for autologous stem cell transplantation. The study is assessing daratumumab in combination with bortezomib, melphalan and prednisone (VMP) vs. VMP alone, and it met its primary endpoint of improving progression-free survival (PFS) at an interim analysis.
Daratumumab treatment reduced the risk of disease progression or death by 50 percent compared to those not treated with the compound. Median PFS for the combination regimen has not yet been reached, while the median PFS for VMP alone is estimated at 18.1 months. Daratumumab is a human IgG1k monoclonal antibody and binds with high affinity to the CD38 molecule. The safety profile of daratumumab combined with the VMP regimen is consistent with the separate safety profiles of both treatment options.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.